Cellular Oncology

Group leader: Ander Matheu Fernández, Ph.D.

Biogipuzkoa HRI. Ikerbasque Research Associate ander.matheufernandez@bio-gipuzkoa.eus
Ander Matheu Fernández obtained his PhD under the direction of Dr. Manuel Serrano at the CNIO (Spanish National Cancer Research Centre) in 2005, and completed his postdoctoral training at the laboratory of Dr. Robin Lovell-Badge at the MRC-NIMR (London) from 2006 until 2011.
In 2011 he joined the Biogipuzkoa HRI as a Miguel Servet researcher (ISCIII) to head the Cellular Oncology Research Group. Since his incorporation, he has composed the multidisciplinary team of 20 members who work with him today. Dr. Matheu has participated in 95 publications in high-impact scientific journals (including Nature, Cell and Cell Stem Cell), more than 75 of them since joining Biogipuzkoa, and being a senior author in 40 of them. He has also headed the writing of five book chapters and is the co-inventor of four patents at both national and international level.
Dr. Matheu has led 25 national and international research projects, participating in more than 55 as a collaborator. These projects represent a total sum of €15 million, more than €6 million of which were awarded to his Research Group. His Group is part of the CIBERfes (Network Centre for Biomedical Research in Frailty and Healthy Ageing) and he is Associate Professor at the University of the Basque Country (UPV/EHU), being a Ikerbasque Research Associate. He has directed 11 doctoral theses between researchers of the Biogipuzkoa HRI and doctors at the Donostia University Hospital (Donostialdea IHO) and has also supervised the final projects of more than 20 bachelor’s and master’s degree students.

Strategic Objectives

The interest of Dr Matheu’s group originally focused on the characterisation of glioma stem cells and the identification of molecular mechanisms related with the ageing of neural stem cells. Hence its original name of Neuro-oncology. However, the research lines of the group have increased and extended and today include knowledge of the molecular mechanisms responsible for regulating cell plasticity and heterogeneity, their role in cancer and ageing processes, and the translation of this knowledge into clinical practice.

Main lines of research

Within the line of cancer research, the objectives of his group consist of:  

  • Determining the signalling pathways regulating the subpopulation of cancer stem cells present in the neoplasms of the central nervous system (CNS) and gastrointestinal cancers
  • Studying the impact of cancer stem cells on the origin and progression/metastasis of the cancer
  • Identifying molecular targets and markers of prognosis and/or response to treatment making it possible to establish alternative therapeutic strategies and stratification patterns of patients in Pediatric CNS tumours, and (iv) generating and/or validating pharmacological agents against cancer stem cells.

Within the line of research in ageing, the objectives consist of:

  • Looking for biomarkers enabling the early detection of frailty and neurodegenerative diseases
  • Identifying the mechanisms responsible for the successful ageing typical of 100 year-olds
  • Characterising CNS and muscle stem cells in the search for molecular targets to palliate the functional decline associated with ageing and neurodegenerative pathologies.

 

Team Members

Name Surname
Center E-mail
Itxaso Aguirre Zuazo Biogipuzkoa HRI itxaso.aguirrezuazo@bio-gipuzkoa.eus
Sara Arevalo Lobera Donostialdea IHO sara.arevalolobera@osakidetza.eus
Aizpea Artetxe Zurutuza Biogipuzkoa HRI aizpea.artetxe@bio-gipuzkoa.eus
Estefanía Carrasco García Biogipuzkoa HRI estefania.carrasco@bio-gipuzkoa.eus
Fernando Cossio Mora UPV – EHU fp.cossio@ehu.es
Sara Cruces Salguero Biogipuzkoa HRI sara.crucessalguero@bio-gipuzkoa.eus
Larraitz Egaña Otaño Donostialdea IHO larraitz.eganaotano@osakidetza.eus
Joseba Elizazu Perez Biogipuzkoa HRI joseba.elizazu@bio-gipuzkoa.eus
Nerea Iturrioz Rodriguez  Biogipuzkoa HRI nerea.iturriozrodriguez@bio-gipuzkoa.eus
Diego Marcos Pérez Biogipuzkoa HRI diego.marcos@bio-gipuzkoa.eus
Verónica Moncho Amor CIBERNED veronica.moncho@bio-gipuzkoa.eus
Manuel Moreno Valladares Donostialdea IHO manuel.morenovalladares@osakidetza.eus
David Ignacio Ortiz De Urbina Ugarte Onkologikoa Fundazioa dortiz@onkologikoa.org
Maddalen Otaegi Ugartemendia Biogipuzkoa HRI maddalen.otaegi@bio-gipuzkoa.eus
Irune Ruiz Diaz Donostialdea IHO irune.ruizdiaz@osakidetza.eus
Ander Saenz Antoñanzas Biogipuzkoa HRI ander.saenz@bio-gipuzkoa.eus
Nicolas Sampron Lebed Donostialdea IHO nicolasmanuel.sampronlebed@osakidetza.eus
Jhonatan Andrés Vergara Arce Biogipuzkoa HRI jhonatanandres.vergaraarce@bio-gipuzkoa.eus
Jorge Alberto Villanua Bernues OSATEK jvillanua@osatek.net

Scientific Output

EUNETCC. THE EUROPEAN COMPREHENSIVE CANCER CENTRE NETWORK. JOINT ACTION.
Código: EU4H/2023/JA/BA-03/EUNETCCC
Investigador Principal (IP): SARA AREVALO LOBERA
Entidad Financiadora: COMISION EUROPEA - HORIZON EUROPE
Fecha de Inicio: 2024-10-01
Fecha de finalización: 2028-09-30
Importe Concedido: 222.879,00 €
PLATAFORMA PARA LA MONITORIZACIÓN DE LA FRAGILIDAD (FRAILPLAT)
Código: PMPTA23/00038
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2024-01-01
Fecha de finalización: 2025-12-31
Importe Concedido: 283.382,00 €
CAPACIDAD FUNCIONAL DE LAS PERSONAS MAYORES: FACTORES DETERMINANTES Y ESTRATEGIAS PARA SU PROTECCION Y FOMENTO
Código: 019-1214601
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: LEHENDAKARITZA
Fecha de Inicio: 2023-09-01
Fecha de finalización: 2024-08-31
Importe Concedido: 17.225,00 €
ESTABLECIMIENTO Y VALIDACION DE NOVEDOSA ESTRATEGIA TERAPEUTICA FRENTE A LAS CELULAS MADRE TUMORALES
Código: 2023-CIEN-000005-01
Investigador Principal (IP): VERONICA MONCHO AMOR
Entidad Financiadora: DIPUTACION FORAL GIPUZKOA
Fecha de Inicio: 2023-05-01
Fecha de finalización: 2024-09-30
Importe Concedido: 52.336,00 €
DE ESTUDIOS POBLACIONALES DE CENTENARIOS A TECNOLOGIA LECCIONES DE MODELO ENVEJECIMIENTO SALUDABLE
Código: 2022-EADI-000017-01
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: DIPUTACION FORAL GIPUZKOA
Fecha de Inicio: 2022-11-01
Fecha de finalización: 2024-10-30
Importe Concedido: 63.453,00 €
IDENTIFICACION Y VALIDACION DE LOS MECANISMOS MOLECULARES RESPONSABLES DEL MANTENIMIENTO DE LA ACTIVIDAD COGNITIVA – NUEVO ENFOQUE BIOLOGICO
Código: 2022111069
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: DEPARTAMENTO DE SALUD
Fecha de Inicio: 2022-10-01
Fecha de finalización: 2025-09-30
Importe Concedido: 178.552,72 €
DETERMINACION DE LA FUNCION Y RELEVANCIA CLINICA DEL REGULADOR DE CELULAS MADRE SOX9 EN ENVEJECIMIENTO Y ENFERMEDADES ASOCIADAS
Código: PI22/01905
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2023-01-01
Fecha de finalización: 2025-12-31
Importe Concedido: 220.220,00 €
CARACTERIZACION DE LA FUNCION E IMPACTO CLINICO DE RTL1 Y CGB5 EN CANCER GASTRICO
Código: PI22/00168
Investigador Principal (IP): ESTEFANÍA CARRASCO GARCÍA
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2023-01-01
Fecha de finalización: 2025-12-31
Importe Concedido: 122.815,00 €
INHIBICION DE LA AUTO-RENOVACION FRENTE AL MEDULOBLASTOMA
Código: BIO20/CI/019/BD
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: FUNDACION VASCA DE INNOVACION E INVESTIGACION SANITARIAS
Fecha de Inicio: 2021-05-01
Fecha de finalización: 2025-03-31
Importe Concedido: 81.856,72 €
IDENTIFICACION DE LA FUNCION Y LA RELEVANCIA CLINICA DE SOX2 EN ENVEJECIMIENTO Y ENFERMEDADES ASOCIADAS AL ENVEJECIMIENTO
Código: PI19/01355
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2020-01-01
Fecha de finalización: 2024-06-30
Importe Concedido: 196.020,00 €
CIBERFES - FRAGILIDAD Y ENVEJECIMIENTO
Código: CB16/10/00496
Investigador Principal (IP): ANDER MATHEU FERNANDEZ
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2017-01-01
Fecha de finalización: 2030-12-31
Importe Concedido: 0,00 €